Riyadh | Health

#Secure in your property, #healthy body, & day #food,
it is as if the whole world were brought to you.
— Riyadh (on #X since 2008)
An old clinic owner.

[Riyadh | Health @Riyadh1Health]

#MyFirstTweet
#secure in your property, #healthy body, & day #food, it is as if the whole world were brought to you.
— Riyadh #Health (on #X since 2008)
https://t.co/ds5IIjEFBc

[jack @jack]

just setting up my twttr

[Massimo @Rainmaker1973]

Scientists have created one of the most detailed 3D reconstructions of a human cell (eukaryotic cell) ever produced.

This groundbreaking model, often termed a "Cellular Landscape Cross-Section Through a Eukaryotic Cell," combines data from X-ray tomography, nuclear magnetic resonance (NMR), and cryo-electron microscopy to map molecular structures in extreme detail.

[Świadomy Wodnik CONSCIOUS AQUARIUS @SwiadomyWodnik]

Masz trzeci zestaw zębów. 🦷

Dokładnie teraz.
W twojej szczęce.
W stanie uśpienia. Tłumiony przez pojedyncze białko o nazwie USAG-1.

Miałeś je przez całe życie. Nikt ci tego nie powiedział.

Wrzesień 2024 – Naukowcy ze Szpitala Uniwersyteckiego w Kioto w Japonii rozpoczęli pierwsze na świecie badania kliniczne na ludziach nad lekiem, który AKTYWUJE TE ZĘBY.

Lek nazywa się TRG-035.
Działa poprzez wyszukiwanie i neutralizowanie białka USAG-1 – molekularnego zamka, który utrzymuje twój trzeci zestaw zębów w stanie uśpienia.

Gdy zamek się otworzy – ząbkowanie otrzymuje sygnał rozwojowy, na który czekało od urodzenia. I zaczyna rosnąć.

Badania na zwierzętach wykazały już powstawanie kompletnych, sprawnych zębów u myszy i fretek. Jedna iniekcja. Naturalne zęby. Doskonale zintegrowane.

Badania kliniczne na ludziach trwają właśnie teraz. 30 dorosłych. Brakujące zęby. Kioto, Japonia.

Jeśli wszystko pójdzie dobrze – data dostępności: 2030.

Żadnych protez.
Żadnych implantów.
Twoje własne.
Naturalnie. Odrosną.

"Pomysł, by sprawić, że wyrosną nowe zęby, jest marzeniem każdego dentysty."
✍️ Dr Katsu Takahashi, główny badacz

Przyszłość stomatologii nie nadchodzi. Już się zaczęła.

[Berci Meskó, MD, PhD @Berci]

Blood draw was prone to automation!

The question is: how much time will it take you to trust the robot with such a delicate process?

I've been following Vitestra closely for years: they have made a technological development into a patented and regulated service.

This new video shows their Aletta® Autonomous Robotic Phlebotomy Device™ performing a diagnostic blood draw.

The patient sits in, the robot finds a suitable vein with ultrasound, helps position the arm and performs sample collection and bandage application. If multiple tubes are needed, it will fill them one by one. Everything is automated.

The device is CE marked in Europe, but in the US, it is an investigational device and is not yet approved by the FDA. That will come too.

I'd be the first one to give it a try!

[Dr sthanu subramanian @drsthanus]

Sacral plexus...

https://t.co/L9IrlSHEyc

[Dr Tariq Tramboo @tariqtramboo]

In this pic, L3- 4 disc bulge is pressing the nerve that goes down to leg.

How’s your Lumbar spine anatomy? H/t @OGdukeneurosurg #Sciatica

[Axios @axios]

Doctors rally behind autonomous vehicles as public health issue https://t.co/itR6E1kqAk

[Global Health NOW @ghn_news]

New 3D images reveal the clitoris’s complex nerve network, highlighting long‑standing gaps in medical understanding of the female body. https://t.co/As01yoZRP9

[SciePro @SciePro]

The clitoris: a complex organ with both external and internal structures, playing a key role in female sexual pleasure and health. #ClitorisAnatomy #SexualHealth

[China Focus @China__Focus]

The world's first prescription for a groundbreaking monoclonal antibody treatment for the hepatitis D virus has been issued recently at a Beijing hospital.

As the first monoclonal antibody ever approved for viral hepatitis worldwide, the drug Libevitug is a monoclonal antibody that works by blocking hepatitis B and D viruses from entering liver cells.

Of the over 254 million chronic hepatitis B carriers worldwide, approximately 5% are co-infected with the hepatitis D virus, and patients with co-infection have long lacked effective targeted therapies.

[Oscar Patel @OscarPatel]

The Way You Walk Changes Your Facial Structure

[Krishna Kannan @Kannan9900]

Aging research is gaining lots of momentum
> Senescent cells go for self-destruction
> In an entirely another study, liver cells are being programmed to acquire thymic cell characteristics and gain youthful immune function.
> Other studies on exercise physiology.

[Global Health Observ @GlobalPHObserv]

Exclusive: AI Bests Virus Experts, Raising Biohazard Fears https://t.co/3GLgLrOyaf

[Science Advances @ScienceAdvances]

A new blood plasma test can distinguish between HIV vaccine-based false positives and true infection with 98% specificity and 95% sensitivity in the clinic. https://t.co/eZE5a86yqj

[BDJ Portfolio @The_BDJ]

FREE TO READ: What is the diagnostic accuracy of sequential vital staining and what is its influence as a visual behavioural motivator to encourage tobacco cessation among tobacco users? Read more in BDJ Open https://t.co/B2Owp9zvK3

[Riyadh | Health @Riyadh1Health]

...Experiments on animal models have shown great success, and we hope that the results on paralyzed humans will be equally promising.
...أظهرت التجارب على النماذج الحيوانية نجاحاً باهراً، ونأمل أن تكون النتائج على البشر المشلولين واعدة بنفس القدر.

[Riyadh | Health @Riyadh1Health]

the world’s first-ever human spinal cord implant using a patient’s own cells, a medical breakthrough that could allow paralyzed patients to stand and walk again
أول زرع في الحبل الشوكي البشري في العالم باستخدام خلايا المريض نفسها، اختراق طبي قد يسمح للمرضى المصابين بالوقوف والمشي

[Cambridge UP - Medicine & Health Sciences @CUP_med_health]

Check out the latest #PaperOfTheMonth from @LaryngolAndOtol
#Laryngology #Otology
📚 https://t.co/hfo5SVUX75

[AHA Science @AHAScience]

The CORALreef study showed in a diverse population, once daily oral enlicitide achieved significant reductions in LDL-C at 24 weeks and sustained through 52 weeks. Enlicitide was relatively safe compared to placebo.

More from @VietHeartPA on the trial presented at #AHA25

[JAMA @JAMA_current]

Among adults with HeFH who were already taking statin therapy, treatment with enlicitide was well tolerated and reduced levels of LDL-C, apolipoprotein B, non–HDL-C, and lipoprotein(a).

https://t.co/7wBj9GjAue